250 related articles for article (PubMed ID: 11034254)
1. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
3. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
4. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
[TBL] [Abstract][Full Text] [Related]
6. Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping.
Hoskins JM; Shenfield GM; Gross AS
J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(1):81-7. PubMed ID: 9300912
[TBL] [Abstract][Full Text] [Related]
7. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.
Baumann P; Meyer JW; Amey M; Baettig D; Bryois C; Jonzier-Perey M; Koeb L; Monney C; Woggon B
Ther Drug Monit; 1992 Feb; 14(1):1-8. PubMed ID: 1546384
[TBL] [Abstract][Full Text] [Related]
8. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration.
Endres HG; Henschel L; Merkel U; Hippius M; Hoffmann A
Pharmazie; 1996 Jan; 51(1):46-51. PubMed ID: 8999435
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
12. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
13. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
[TBL] [Abstract][Full Text] [Related]
14. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
16. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
[TBL] [Abstract][Full Text] [Related]
17. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
18. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
19. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
Hägg S; Spigset O; Dahlqvist R
Br J Clin Pharmacol; 2001 Feb; 51(2):169-73. PubMed ID: 11259990
[TBL] [Abstract][Full Text] [Related]
20. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.
Evans DA; Krahn P; Narayanan N
Pharmacogenetics; 1995 Apr; 5(2):64-71. PubMed ID: 7663530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]